The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.
Leigha Senter, Shelly Hovick, Rachel Notestine et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the impact of genotype-informed personalized cancer risk estimates (GRE) versus standard lifetime cancer risk estimates (SRE) on decisional conflict in women with BRCA1/BRCA2 pathogenic variants. The study found no differences in decisional conflict between the two groups at follow-up, although the SRE group reported increased perceived stress and a decreased need for personal structure compared to the GRE group.
Key findings
- No differences in decisional conflict between GRE and SRE arms at follow-up.
- SRE arm participants showed decreased decisional conflict compared to baseline (P = 0.003).
- SRE arm participants reported increased perceived stress at follow-up (P = 0.02).
- GRE arm participants had a decreased need for personal structure compared to SRE (P = 0.02).
Why it matters
Understanding how different risk communication strategies affect decision-making is crucial for clinicians managing patients with BRCA1/BRCA2 pathogenic variants. This study highlights the complexities of risk management and the need for tailored approaches in patient education.